Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

MINDRAY In-Vitro Diagnostics

As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App





Mindray Hematology Analyzers Measure Increased Eosinophil Count Associated with Subprophylactic Anticoagulation in COVID-19 Patients

By LabMedica International staff writers
Posted on 26 Apr 2021
Mindray (Shenzhen, China) hematology analyzers are using advanced technologies to detect increased eosinophil count that is associated with the level of subprophylactic anticoagulation in COVID-19 patients.

Is prophylactic anticoagulant therapy a common treatment for clinicians to deal with thrombotic events in COVID-19? More...
Is there a connection between the eosinophil count and anticoagulation monitoring in COVID-19 patients? Thrombosis has emerged as an important complication among hospitalized patients with COVID-19. A prothrombotic state induced by SARS-Cov-2 can manifest in venous thromboembolism (VTE), arterial thrombosis and disseminated intravenous coagulation (DIC). In 28 studies including 2928 patients, thrombotic complications occurred in 34% of ICU patients, deep venous thrombosis (DVT) reported in 16.1% and pulmonary embolism in 12.6% of patients, and were associated with high mortality.

Low molecular weight heparin (LMWH) and unfractionated heparin (UFH) are recommended by the international society for thrombosis on hemostasis (ISTH), American Society of Hematology (ASH) for the treatment of thrombotic events associated with SARS-CoV-2 infection. Particularly, LMWH has a stronger antithrombotic effect than UFH. LMWH predominantly acts on factor Xa. For this reason, LMWH activity is monitored using serum anti-factor Xa activity (AFXa) levels instead of activated Partial Thromboplastin Time (aPTT). Enoxaparin is one of the most important LMWH. The AFXa level reached peak 3-5 hours after administration. The AFXa levels below 0.2 IU/mL may increase the risk of VTE in COVID-19 patients, due to the hypercoagulability.

Dr. Selma Ari has found the increased eosinophil count is associated with the level of subprophylactic anticoagulation in COVID-19 patients. In the laboratory results, only eosinophil counts and AFXa are significantly different between subprophylactic anticoagulation group and prophylactic anticoagulation group when the patients are admitted to hospital. Laboratory analysis collected before the discharge of patients revealed that eosinophil counts in subprophylactic anticoagulation group were higher than in prophylactic anticoagulation group , whereas AFXa were lower in subprophylactic anticoagulation group. Eosinophil induces platelet aggregation and thrombus formation through the production of major basic protein (MBP) and eosinophil peroxidase (EPX). Enzymes released from eosinophils (peroxidases, cationic proteins, and neurotoxins) may decrease the anticoagulant activity of heparin.

In this study, in subprophylactic anticoagulation group, high eosinophil levels had lower anticoagulant activity in COVID-19 patients. Eosinophil counts were examined with Mindray BC- 6800 auto hematology analyzer. Its SF Cube analysis technology can produce three-dimensional scattergram which can help doctors better identify and differentiate blood cell populations, especially to reveal abnormal cell population undetected by other techniques. Nowadays a large number of parameters on BC-6800 can be used in clinical diagnosis and scientific research. Therefore, clinicians are welcome to do more research on COVID-19 on Mindray BC-6200/BC-6800/BC-6800Plus/ CAL 6000/CAL 8000.




Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.